ZielBio raises $25M series A to advance two new cancer targets

ZielBio raised a $25 million series A round from Morningside and Partners Innovation Fund to advance a functional proteomics platform that has generated two first-in-class preclinical mAbs targeting CSP1 and HRNR.

The company was founded in 2010 by University of Virginia professor Kimberly Kelly with about

Read the full 455 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE